Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The European Commission has granted marketing authorisation for GlaxoSmithKline (GSK) and Genmab's Arzerra as first-line treatment for chronic lymphocytic leukaemia in combination with chlorambucil or bendamustine for patients ineligible for fludarabine-based therapy.
Subscribe to our email newsletter
The marketing authorisation is for a new indication for the use of Arzerra (ofatumumab) in combination with chlorambucil or bendamustine to treat patients with chronic lymphocytic leukaemia (CLL) who have not received prior therapy and who are not eligible for fludarabine-based therapy.
Genmab CEO Jan van de Winkel said that the company is happy to receive this decision that Arzerra is approved in the EU in the front-line setting in combination with two different alkylating chemotherapies.
"This is another important milestone and we look forward to a successful launch under this new indication of the drug in Europe in the coming months. We hope to receive additional approvals in frontline across the globe in the future," Winkel added.
The EC authorisation for Arzerra is based on positive data from two clinical trials, including a Phase III trial and a Phase II trial.
The randomized, multicentre Phase III trial (OMB110911, COMPLEMENT 1) evaluated the combination of ofatumumab and chlorambucil versus chlorambucil alone in CLL patients.
The company said that results from the open-label, parallel-arm, pivotal trial showed that the combination statistically improved median progression-free survival compared to chlorambucil alone.
The Phase II trial (OMB115991) evaluated ofatumumab in combination with bendamustine in 44 patients with previously untreated CLL.